Web interface-supported transmission risk assessment and cost-effectiveness analysis of postdonation screening: a global model applied to Ghana, Thailand, and the Netherlands
Identifieur interne : 000B11 ( Main/Exploration ); précédent : 000B10; suivant : 000B12Web interface-supported transmission risk assessment and cost-effectiveness analysis of postdonation screening: a global model applied to Ghana, Thailand, and the Netherlands
Auteurs : Marinus Van Hulst [Pays-Bas, Suisse, Ghana, Thaïlande] ; Gijs A. A. Hubben ; Kwamena W. C. Sagoe ; Charupon Promwong ; Parichart Permpikul ; Ladda Fongsatitkul ; Diarmuid M. Glynn ; Cees T. Smit Sibinga ; Maarten J. PostmaSource :
- Transfusion : (Philadelphia, PA) [ 0041-1132 ] ; 2009.
Descripteurs français
- Pascal (Inist)
- Wicri :
- geographic : Pays-Bas.
English descriptors
- KwdEn :
Abstract
BACKGROUND: The goal of our research was to actively involve decision makers in the economic assessment of screening strategies in their region. This study attempted to accomplish this by providing an easy-to-use Web interface at http://www.bloodsafety.info that allows decision makers to adapt this model to local conditions. STUDY DESIGN AND METHODS: The cost-effectiveness was compared of 1) adding antigen screening to antibody screening for hepatitis C virus (HCV) and human immunodeficiency virus (HIV); 2) adding nucleic acid amplification testing (NAT) on hepatitis B virus (HBV), HCV, and HIV in minipool (pool of 6 [MP6] and 24 [MP24]) to antibody screening and hepatitis B surface antigen (HBsAg) screening; and 3) individual-donation NAT on HBV, HCV, and HIV to antibody screening and HBsAg screening for Ghana, Thailand, and the Netherlands. RESULTS: The combination of HCV antibody-antigen combination (combo) and HIV combo added to antibody screening in Ghana and Thailand was cost-effective according to the WHO criteria. MP24-NAT screening in Ghana was also cost-effective. MP24-NAT on HBV, HCV, and HIV was not cost-effective compared to the other screening strategies evaluated for the Netherlands. Large regional differences in cost-effectiveness were found for Thailand. CONCLUSION: The young transfusion recipient population of Ghana in combination with a high risk of viral transmission yields better cost-effectiveness for additional tests. The advanced age of the transfused population of the Netherlands and a small risk of viral transmission gives poor cost-effectiveness for more sensitive screening techniques. It was demonstrated that a global health economic model combined with a Web interface can provide easy access to risk assessment and cost-effectiveness analysis.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000044
- to stream PascalFrancis, to step Curation: 000089
- to stream PascalFrancis, to step Checkpoint: 000040
- to stream Main, to step Merge: 000B28
- to stream Main, to step Curation: 000B11
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Web interface-supported transmission risk assessment and cost-effectiveness analysis of postdonation screening: a global model applied to Ghana, Thailand, and the Netherlands</title><author><name sortKey="Van Hulst, Marinus" sort="Van Hulst, Marinus" uniqKey="Van Hulst M" first="Marinus" last="Van Hulst">Marinus Van Hulst</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Unit of PharmacoEpidemiology and Pharmaco-Economics (PE<sup>2</sup>), Department of Pharmacy, University of Groningen</s1><s3>NLD</s3></inist:fA14><country>Pays-Bas</country></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Clinical Pharmacy and Toxicology, Martini Hospital; and Health Economics Consultancy and Technology Assessments (HECTA)</s1><s2>Groningen</s2><s3>NLD</s3></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>BaseCase GmbH Decision Support Software</s1><s2>Zug</s2><s3>CHE</s3></inist:fA14><country>Suisse</country><wicri:noRegion>BaseCase GmbH Decision Support Software</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Department of Microbiology, University of Ghana Medical School</s1><s2>Accra</s2><s3>GHA</s3></inist:fA14><country>Ghana</country><placeName><settlement type="city">Accra</settlement><region nuts="2">Région du Grand Accra</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Blood Bank and Transfusion Medicine Unit, Faculty of Medicine, Prince of Songkla University</s1><s2>Songkla</s2><s3>THA</s3></inist:fA14><country>Thaïlande</country><wicri:noRegion>Songkla</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Transfusion Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; the Blood Bank Unit, Faculty of Medicine, Chiang Mai University</s1><s2>Chiang Mai</s2><s3>THA</s3></inist:fA14><country>Thaïlande</country><wicri:noRegion>Chiang Mai</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Academic Institute for International Development of Transfusion Medicine, Sanquin Consulting Services and WHO Collaborating Centre for Blood Transfusion</s1><s2>Groningen</s2><s3>NLD</s3></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName></affiliation></author><author><name sortKey="Hubben, Gijs A A" sort="Hubben, Gijs A A" uniqKey="Hubben G" first="Gijs A. A." last="Hubben">Gijs A. A. Hubben</name></author><author><name sortKey="Sagoe, Kwamena W C" sort="Sagoe, Kwamena W C" uniqKey="Sagoe K" first="Kwamena W. C." last="Sagoe">Kwamena W. C. Sagoe</name></author><author><name sortKey="Promwong, Charupon" sort="Promwong, Charupon" uniqKey="Promwong C" first="Charupon" last="Promwong">Charupon Promwong</name></author><author><name sortKey="Permpikul, Parichart" sort="Permpikul, Parichart" uniqKey="Permpikul P" first="Parichart" last="Permpikul">Parichart Permpikul</name></author><author><name sortKey="Fongsatitkul, Ladda" sort="Fongsatitkul, Ladda" uniqKey="Fongsatitkul L" first="Ladda" last="Fongsatitkul">Ladda Fongsatitkul</name></author><author><name sortKey="Glynn, Diarmuid M" sort="Glynn, Diarmuid M" uniqKey="Glynn D" first="Diarmuid M." last="Glynn">Diarmuid M. Glynn</name></author><author><name sortKey="Smit Sibinga, Cees T" sort="Smit Sibinga, Cees T" uniqKey="Smit Sibinga C" first="Cees T." last="Smit Sibinga">Cees T. Smit Sibinga</name></author><author><name sortKey="Postma, Maarten J" sort="Postma, Maarten J" uniqKey="Postma M" first="Maarten J." last="Postma">Maarten J. Postma</name></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">10-0031038</idno><date when="2009">2009</date><idno type="stanalyst">PASCAL 10-0031038 INIST</idno><idno type="RBID">Pascal:10-0031038</idno><idno type="wicri:Area/PascalFrancis/Corpus">000044</idno><idno type="wicri:Area/PascalFrancis/Curation">000089</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000040</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000040</idno><idno type="wicri:doubleKey">0041-1132:2009:Van Hulst M:web:interface:supported</idno><idno type="wicri:Area/Main/Merge">000B28</idno><idno type="wicri:Area/Main/Curation">000B11</idno><idno type="wicri:Area/Main/Exploration">000B11</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Web interface-supported transmission risk assessment and cost-effectiveness analysis of postdonation screening: a global model applied to Ghana, Thailand, and the Netherlands</title><author><name sortKey="Van Hulst, Marinus" sort="Van Hulst, Marinus" uniqKey="Van Hulst M" first="Marinus" last="Van Hulst">Marinus Van Hulst</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Unit of PharmacoEpidemiology and Pharmaco-Economics (PE<sup>2</sup>), Department of Pharmacy, University of Groningen</s1><s3>NLD</s3></inist:fA14><country>Pays-Bas</country></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Clinical Pharmacy and Toxicology, Martini Hospital; and Health Economics Consultancy and Technology Assessments (HECTA)</s1><s2>Groningen</s2><s3>NLD</s3></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>BaseCase GmbH Decision Support Software</s1><s2>Zug</s2><s3>CHE</s3></inist:fA14><country>Suisse</country><wicri:noRegion>BaseCase GmbH Decision Support Software</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Department of Microbiology, University of Ghana Medical School</s1><s2>Accra</s2><s3>GHA</s3></inist:fA14><country>Ghana</country><placeName><settlement type="city">Accra</settlement><region nuts="2">Région du Grand Accra</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Blood Bank and Transfusion Medicine Unit, Faculty of Medicine, Prince of Songkla University</s1><s2>Songkla</s2><s3>THA</s3></inist:fA14><country>Thaïlande</country><wicri:noRegion>Songkla</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Transfusion Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; the Blood Bank Unit, Faculty of Medicine, Chiang Mai University</s1><s2>Chiang Mai</s2><s3>THA</s3></inist:fA14><country>Thaïlande</country><wicri:noRegion>Chiang Mai</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Academic Institute for International Development of Transfusion Medicine, Sanquin Consulting Services and WHO Collaborating Centre for Blood Transfusion</s1><s2>Groningen</s2><s3>NLD</s3></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName></affiliation></author><author><name sortKey="Hubben, Gijs A A" sort="Hubben, Gijs A A" uniqKey="Hubben G" first="Gijs A. A." last="Hubben">Gijs A. A. Hubben</name></author><author><name sortKey="Sagoe, Kwamena W C" sort="Sagoe, Kwamena W C" uniqKey="Sagoe K" first="Kwamena W. C." last="Sagoe">Kwamena W. C. Sagoe</name></author><author><name sortKey="Promwong, Charupon" sort="Promwong, Charupon" uniqKey="Promwong C" first="Charupon" last="Promwong">Charupon Promwong</name></author><author><name sortKey="Permpikul, Parichart" sort="Permpikul, Parichart" uniqKey="Permpikul P" first="Parichart" last="Permpikul">Parichart Permpikul</name></author><author><name sortKey="Fongsatitkul, Ladda" sort="Fongsatitkul, Ladda" uniqKey="Fongsatitkul L" first="Ladda" last="Fongsatitkul">Ladda Fongsatitkul</name></author><author><name sortKey="Glynn, Diarmuid M" sort="Glynn, Diarmuid M" uniqKey="Glynn D" first="Diarmuid M." last="Glynn">Diarmuid M. Glynn</name></author><author><name sortKey="Smit Sibinga, Cees T" sort="Smit Sibinga, Cees T" uniqKey="Smit Sibinga C" first="Cees T." last="Smit Sibinga">Cees T. Smit Sibinga</name></author><author><name sortKey="Postma, Maarten J" sort="Postma, Maarten J" uniqKey="Postma M" first="Maarten J." last="Postma">Maarten J. Postma</name></author></analytic><series><title level="j" type="main">Transfusion : (Philadelphia, PA)</title><title level="j" type="abbreviated">Transfusion : (Phila., PA)</title><idno type="ISSN">0041-1132</idno><imprint><date when="2009">2009</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Transfusion : (Philadelphia, PA)</title><title level="j" type="abbreviated">Transfusion : (Phila., PA)</title><idno type="ISSN">0041-1132</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cost analysis</term><term>Cost efficiency analysis</term><term>Interface</term><term>Medical screening</term><term>Netherlands</term><term>Risk analysis</term><term>Transfusion</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Interface</term><term>Analyse risque</term><term>Analyse coût</term><term>Analyse coût efficacité</term><term>Dépistage</term><term>Pays-Bas</term><term>Transfusion</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Pays-Bas</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">BACKGROUND: The goal of our research was to actively involve decision makers in the economic assessment of screening strategies in their region. This study attempted to accomplish this by providing an easy-to-use Web interface at http://www.bloodsafety.info that allows decision makers to adapt this model to local conditions. STUDY DESIGN AND METHODS: The cost-effectiveness was compared of 1) adding antigen screening to antibody screening for hepatitis C virus (HCV) and human immunodeficiency virus (HIV); 2) adding nucleic acid amplification testing (NAT) on hepatitis B virus (HBV), HCV, and HIV in minipool (pool of 6 [MP6] and 24 [MP24]) to antibody screening and hepatitis B surface antigen (HBsAg) screening; and 3) individual-donation NAT on HBV, HCV, and HIV to antibody screening and HBsAg screening for Ghana, Thailand, and the Netherlands. RESULTS: The combination of HCV antibody-antigen combination (combo) and HIV combo added to antibody screening in Ghana and Thailand was cost-effective according to the WHO criteria. MP24-NAT screening in Ghana was also cost-effective. MP24-NAT on HBV, HCV, and HIV was not cost-effective compared to the other screening strategies evaluated for the Netherlands. Large regional differences in cost-effectiveness were found for Thailand. CONCLUSION: The young transfusion recipient population of Ghana in combination with a high risk of viral transmission yields better cost-effectiveness for additional tests. The advanced age of the transfused population of the Netherlands and a small risk of viral transmission gives poor cost-effectiveness for more sensitive screening techniques. It was demonstrated that a global health economic model combined with a Web interface can provide easy access to risk assessment and cost-effectiveness analysis.</div></front></TEI><affiliations><list><country><li>Ghana</li><li>Pays-Bas</li><li>Suisse</li><li>Thaïlande</li></country><region><li>Groningue (province)</li><li>Région du Grand Accra</li></region><settlement><li>Accra</li><li>Groningue</li></settlement></list><tree><noCountry><name sortKey="Fongsatitkul, Ladda" sort="Fongsatitkul, Ladda" uniqKey="Fongsatitkul L" first="Ladda" last="Fongsatitkul">Ladda Fongsatitkul</name><name sortKey="Glynn, Diarmuid M" sort="Glynn, Diarmuid M" uniqKey="Glynn D" first="Diarmuid M." last="Glynn">Diarmuid M. Glynn</name><name sortKey="Hubben, Gijs A A" sort="Hubben, Gijs A A" uniqKey="Hubben G" first="Gijs A. A." last="Hubben">Gijs A. A. Hubben</name><name sortKey="Permpikul, Parichart" sort="Permpikul, Parichart" uniqKey="Permpikul P" first="Parichart" last="Permpikul">Parichart Permpikul</name><name sortKey="Postma, Maarten J" sort="Postma, Maarten J" uniqKey="Postma M" first="Maarten J." last="Postma">Maarten J. Postma</name><name sortKey="Promwong, Charupon" sort="Promwong, Charupon" uniqKey="Promwong C" first="Charupon" last="Promwong">Charupon Promwong</name><name sortKey="Sagoe, Kwamena W C" sort="Sagoe, Kwamena W C" uniqKey="Sagoe K" first="Kwamena W. C." last="Sagoe">Kwamena W. C. Sagoe</name><name sortKey="Smit Sibinga, Cees T" sort="Smit Sibinga, Cees T" uniqKey="Smit Sibinga C" first="Cees T." last="Smit Sibinga">Cees T. Smit Sibinga</name></noCountry><country name="Pays-Bas"><noRegion><name sortKey="Van Hulst, Marinus" sort="Van Hulst, Marinus" uniqKey="Van Hulst M" first="Marinus" last="Van Hulst">Marinus Van Hulst</name></noRegion><name sortKey="Van Hulst, Marinus" sort="Van Hulst, Marinus" uniqKey="Van Hulst M" first="Marinus" last="Van Hulst">Marinus Van Hulst</name><name sortKey="Van Hulst, Marinus" sort="Van Hulst, Marinus" uniqKey="Van Hulst M" first="Marinus" last="Van Hulst">Marinus Van Hulst</name></country><country name="Suisse"><noRegion><name sortKey="Van Hulst, Marinus" sort="Van Hulst, Marinus" uniqKey="Van Hulst M" first="Marinus" last="Van Hulst">Marinus Van Hulst</name></noRegion></country><country name="Ghana"><region name="Région du Grand Accra"><name sortKey="Van Hulst, Marinus" sort="Van Hulst, Marinus" uniqKey="Van Hulst M" first="Marinus" last="Van Hulst">Marinus Van Hulst</name></region></country><country name="Thaïlande"><noRegion><name sortKey="Van Hulst, Marinus" sort="Van Hulst, Marinus" uniqKey="Van Hulst M" first="Marinus" last="Van Hulst">Marinus Van Hulst</name></noRegion><name sortKey="Van Hulst, Marinus" sort="Van Hulst, Marinus" uniqKey="Van Hulst M" first="Marinus" last="Van Hulst">Marinus Van Hulst</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B11 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000B11 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:10-0031038
|texte= Web interface-supported transmission risk assessment and cost-effectiveness analysis of postdonation screening: a global model applied to Ghana, Thailand, and the Netherlands
}}
| This area was generated with Dilib version V0.6.31. |  |